Please wait while the formulary information is being retrieved.
Drug overview for IODOPEN (sodium iodide):
Generic name: SODIUM IODIDE
Drug class: Iodine
Therapeutic class: Electrolyte Balance-Nutritional Products
No enhanced Introduction information available for this drug.
No enhanced Uses information available for this drug.
Generic name: SODIUM IODIDE
Drug class: Iodine
Therapeutic class: Electrolyte Balance-Nutritional Products
No enhanced Introduction information available for this drug.
No enhanced Uses information available for this drug.
DRUG IMAGES
IODOPEN 100 MCG/ML VIAL
The following indications for IODOPEN (sodium iodide) have been approved by the FDA:
Indications:
Iodine deficiency
Professional Synonyms:
None.
Indications:
Iodine deficiency
Professional Synonyms:
None.
The following dosing information is available for IODOPEN (sodium iodide):
No enhanced Dosing information available for this drug.
No enhanced Administration information available for this drug.
No dosing information available.
No generic dosing information available.
The following drug interaction information is available for IODOPEN (sodium iodide):
There are 0 contraindications.
There are 2 severe interactions.
These drug interactions can produce serious consequences in most patients. Actions required for severe interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration scheduling, and providing additional patient monitoring. Review the full interaction monograph for more information.
| Drug Interaction | Drug Names |
|---|---|
| Radioactive Iodide/Agents that Affect Iodide SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Many compounds can affect iodide protein binding and alter iodide pharmacokinetics and pharmacodynamics.(1) CLINICAL EFFECTS: Compounds that affect iodide pharmacokinetics and pharmacodynamics may impact the effectiveness of radioactive iodide.(1) PREDISPOSING FACTORS: Compounds that affect iodide pharmacokinetics and pharmacodynamics are expected to have the most impact during therapy using radioactive iodide. Diagnostic procedures would be expected to be impacted less. PATIENT MANAGEMENT: Discuss the use of agents that affect iodide pharmacokinetics and pharmacodynamics with the patient's oncologist.(1) Because indocyanine green contains sodium iodide, the iodine-binding capacity of thyroid tissue may be reduced for at least one week following administration. Do not perform radioactive iodine uptake studies for at least one week following administration of indocyanine green.(2) The manufacturer of iopamidol states administration may interfere with thyroid uptake of radioactive iodine and decrease therapeutic and diagnostic efficacy. Avoid thyroid therapy or testing for up to 6 weeks post administration of iopamidol.(3) DISCUSSION: Many agents interact with radioactive iodine. The average duration of effect is: anticoagulants - 1 week antihistamines - 1 week anti-thyroid drugs, e.g: carbimazole, methimazole, propylthiouracil - 3-5 days corticosteroids - 1 week iodide-containing medications, e.g: amiodarone - 1-6 months expectorants - 2 weeks Lugol solution - 3 weeks saturated solution of potassium iodine - 3 weeks vitamins - 10-14 days iodide-containing X-ray contrast agents - up to 1 year lithium - 4 weeks phenylbutazone - 1-2 weeks sulfonamides - 1 week thyroid hormones (natural or synthetic), e.g.: thyroxine - 4 weeks tri-iodothyronine - 2 weeks tolbutamide - 1 week topical iodide - 1-9 months (1) |
ADREVIEW, JEANATOPE, MEGATOPE, SODIUM IODIDE I-123 |
| Sodium Iodide I 131/Agents that Affect Iodide SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Many compounds can affect iodide protein binding and alter iodide pharmacokinetics and pharmacodynamics.(1,2) CLINICAL EFFECTS: Compounds that affect iodide pharmacokinetics and pharmacodynamics may impact the effectiveness of radioactive iodide.(1,2) PREDISPOSING FACTORS: Compounds that affect iodide pharmacokinetics and pharmacodynamics are expected to have the most impact during therapy using radioactive iodide. Diagnostic procedures would be expected to be impacted less. PATIENT MANAGEMENT: Discuss the use of agents that affect iodide pharmacokinetics and pharmacodynamics with the patient's oncologist.(1,2) Because indocyanine green contains sodium iodide, the iodine-binding capacity of thyroid tissue may be reduced for at least one week following administration. Do not perform radioactive iodine uptake studies for at least one week following administration of indocyanine green.(3) The manufacturer of iopamidol states administration may interfere with thyroid uptake of radioactive iodine and decrease therapeutic and diagnostic efficacy. Avoid thyroid therapy or testing for up to 6 weeks post administration of iopamidol.(4) DISCUSSION: Many agents interact with radioactive iodine. The average duration of effect is: anticoagulants - 1 week antihistamines - 1 week anti-thyroid drugs, e.g: carbimazole, methimazole, propylthiouracil - 3-5 days corticosteroids - 1 week iodide-containing medications, e.g: amiodarone - 1-6 months expectorants - 2 weeks Lugol solution - 3 weeks saturated solution of potassium iodine - 3 weeks vitamins - 10-14 days iodide-containing X-ray contrast agents - up to 1 year lithium - 4 weeks phenylbutazone - 1-2 weeks sulfonamides - 1 week thyroid hormones (natural or synthetic), e.g.: thyroxine - 4 weeks tri-iodothyronine - 2 weeks tolbutamide - 1 week topical iodide - 1-9 months (1,2) |
HICON, SODIUM IODIDE I-131 |
There are 1 moderate interactions.
The clinician should assess the patient’s characteristics and take action as needed. Actions required for moderate interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration.
| Drug Interaction | Drug Names |
|---|---|
| Lithium/Iodide Salts SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Unknown. CLINICAL EFFECTS: Concurrent administration of lithium and iodide salts may produce hypothyroidism. PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: If both drugs are given, monitor patient for signs and symptoms of hypothyroidism. If hypothyroidism develops, thyroid hormone may be used to treat symptoms. DISCUSSION: Hypothyroidism is a side effect that may occur with long-term lithium treatment. Thyroid gland enlargement and increased thyroid stimulating hormone may also be present. Iodide administration to patients receiving lithium may increase the risk of patients developing hypothyroidism. |
LITHIUM CARBONATE, LITHIUM CARBONATE ER, LITHIUM CITRATE, LITHIUM CITRATE TETRAHYDRATE, LITHOBID |
The following contraindication information is available for IODOPEN (sodium iodide):
Drug contraindication overview.
No enhanced Contraindications information available for this drug.
No enhanced Contraindications information available for this drug.
There are 1 contraindications.
Absolute contraindication.
| Contraindication List |
|---|
| Pregnancy |
There are 3 severe contraindications.
Adequate patient monitoring is recommended for safer drug use.
| Severe List |
|---|
| Hypocomplementemic urticarial vasculitis |
| Kidney disease with reduction in glomerular filtration rate (GFr) |
| Pulmonary tuberculosis |
There are 0 moderate contraindications.
The following adverse reaction information is available for IODOPEN (sodium iodide):
Adverse reaction overview.
No enhanced Common Adverse Effects information available for this drug.
No enhanced Common Adverse Effects information available for this drug.
There are 1 severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
| None. | None. |
| Rare/Very Rare |
|---|
|
Angioedema |
There are 4 less severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
| None. | None. |
| Rare/Very Rare |
|---|
|
Arthralgia Eosinophilia Fever Lymphadenopathy |
The following precautions are available for IODOPEN (sodium iodide):
No enhanced Pediatric Use information available for this drug.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
No enhanced Pregnancy information available for this drug.
No enhanced Lactation information available for this drug.
No enhanced Geriatric Use information available for this drug.
The following prioritized warning is available for IODOPEN (sodium iodide):
No warning message for this drug.
No warning message for this drug.
The following icd codes are available for IODOPEN (sodium iodide)'s list of indications:
| Iodine deficiency | |
| E00 | Congenital iodine-deficiency syndrome |
| E00.0 | Congenital iodine-deficiency syndrome, neurological type |
| E00.1 | Congenital iodine-deficiency syndrome, myxedematous type |
| E00.2 | Congenital iodine-deficiency syndrome, mixed type |
| E00.9 | Congenital iodine-deficiency syndrome, unspecified |
| E01 | Iodine-deficiency related thyroid disorders and allied conditions |
| E01.0 | Iodine-deficiency related diffuse (endemic) goiter |
| E01.1 | Iodine-deficiency related multinodular (endemic) goiter |
| E01.2 | Iodine-deficiency related (endemic) goiter, unspecified |
| E01.8 | Other iodine-deficiency related thyroid disorders and allied conditions |
| E02 | Subclinical iodine-deficiency hypothyroidism |
Formulary Reference Tool